Avoro Capital Advisors LLC Sells 90,000 Shares of Vera Therapeutics, Inc. $VERA

Avoro Capital Advisors LLC decreased its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 1.4% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 6,210,000 shares of the company’s stock after selling 90,000 shares during the period. Vera Therapeutics accounts for about 2.3% of Avoro Capital Advisors LLC’s portfolio, making the stock its 15th largest holding. Avoro Capital Advisors LLC owned 9.73% of Vera Therapeutics worth $180,463,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. UBS Group AG increased its position in Vera Therapeutics by 57.5% during the third quarter. UBS Group AG now owns 162,075 shares of the company’s stock worth $4,710,000 after acquiring an additional 59,142 shares during the period. BNP Paribas Financial Markets increased its holdings in shares of Vera Therapeutics by 129.7% during the third quarter. BNP Paribas Financial Markets now owns 253,976 shares of the company’s stock worth $7,381,000 after purchasing an additional 143,424 shares during the period. Franklin Resources Inc. acquired a new stake in shares of Vera Therapeutics in the third quarter valued at approximately $264,000. Legal & General Group Plc raised its position in shares of Vera Therapeutics by 1.7% in the third quarter. Legal & General Group Plc now owns 51,263 shares of the company’s stock valued at $1,490,000 after buying an additional 845 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in shares of Vera Therapeutics by 10.7% in the third quarter. Russell Investments Group Ltd. now owns 163,169 shares of the company’s stock valued at $4,742,000 after buying an additional 15,705 shares during the period. Institutional investors and hedge funds own 99.21% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on VERA. Cantor Fitzgerald restated an “overweight” rating on shares of Vera Therapeutics in a research note on Wednesday, November 26th. Pivotal Research set a $73.00 price objective on shares of Vera Therapeutics in a research note on Friday, December 5th. Evercore upped their price target on shares of Vera Therapeutics from $75.00 to $97.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. Bank of America lifted their price objective on shares of Vera Therapeutics from $48.00 to $66.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Finally, HC Wainwright boosted their price objective on shares of Vera Therapeutics from $90.00 to $110.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $81.45.

Insider Activity at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 16,925 shares of the firm’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $41.98, for a total value of $710,511.50. Following the completion of the transaction, the chief executive officer directly owned 257,163 shares of the company’s stock, valued at approximately $10,795,702.74. This trade represents a 6.18% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider William D. Turner sold 2,187 shares of Vera Therapeutics stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $41.98, for a total transaction of $91,810.26. Following the completion of the transaction, the insider owned 45,313 shares of the company’s stock, valued at $1,902,239.74. This represents a 4.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 33,490 shares of company stock worth $1,405,910 in the last ninety days. Insiders own 16.30% of the company’s stock.

Vera Therapeutics Stock Performance

NASDAQ:VERA opened at $39.96 on Friday. The company has a market capitalization of $2.80 billion, a P/E ratio of -8.58 and a beta of 1.17. The business has a fifty day simple moving average of $43.81 and a two-hundred day simple moving average of $36.75. The company has a debt-to-equity ratio of 0.12, a current ratio of 13.64 and a quick ratio of 13.64. Vera Therapeutics, Inc. has a 1 year low of $18.53 and a 1 year high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.34) by ($0.05). During the same period in the prior year, the company posted ($0.72) earnings per share. On average, analysts expect that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Vera Therapeutics Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.